Use of 1,1,2-triphenylbut-1-ene derivatives for the manufacture of a medicament for treating Alzheimer's disease

Verwendung von 1,1,2-Triphenylbut-1-en-Derivaten zur Herstellung eines Arzneimittels zur Behandlung der Alzheimerschen Krankheit

Utilisation de dérivés du triphényl-1,1,2-butène-1 pour la fabrication d'un médicament pour le traitement de la maladie d'Alzheimer

Abstract

The use of a compound of the formula (I) or of a pharmaceutically acceptable salt thereof: wherein:-    R 1 and R 2 may be the same or different provided that, when R 1 and R 2 are the same, each is a methyl or ethyl group, and, when R 1 and R 2 are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group for the manufacture of a medicament for the treatment of Alzheimer's Disease.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    DE-4320896-A1January 05, 1995Denecke Rainer Dr Med VetPräparat zur Therapie und Prophylaxe von Demenz-Erkrankungen

NO-Patent Citations (0)

    Title

Cited By (7)

    Publication numberPublication dateAssigneeTitle
    EP-0976404-A2February 02, 2000Pfizer Products Inc.Pharmazeutische Zubereitung zur Vorbeugung und Behandlung von kognitiven Störungen bei Säugetieren
    EP-0976404-A3June 27, 2001Pfizer Products Inc.Compositions pharmaceutiques pour la prévention et la therapie de troubles cognitifes chez les mammifères
    US-6288108-B1September 11, 2001Eli Lilly And CompanyMethods for increasing levels of acetylcholine
    US-6395719-B1May 28, 2002Eli Lilly And CompanyMethods for increasing levels of acetylcholine
    US-6489481-B1December 03, 2002Astrazeneca AbMethod for treating neurological disorders
    WO-0025767-A2May 11, 2000Astrazeneca AbTroubles neurologiques
    WO-0025767-A3September 28, 2000Astrazeneca Ab, Richard Alan Keith, Timothy Martin Piser, Michael Thaddeus KlimasTroubles neurologiques